The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.
In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.
EHA 2021: fixed-duration therapies and sequencing in CLL
The AML Sessions: highlights from ASCO/EHA 2021
EHA 2021: key trial updates in myeloma
Key updates on CAR-T therapy for ALL
The Myeloma Sessions: post-COMY 2021 myeloma patients session
EHA 2021: MRD in myeloma
Latest updates on CAR-T therapy for CLL
The Myeloma Sessions: post-COMy 2021 roundtable
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
MDS Session: Women in Science
Key updates on CAR-T & cellular therapy for AML
The MDS Sessions: highlights from ASH 2020
The Transplant Sessions: ASH 2020 highlights
The Lymphoma Sessions: ASH 2020 highlights
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The Post-EBMT for Trainees VJSessions
Post-ASH Amyloidosis Session from VJHemOnc
The Post EBMT VJSessions from VJHemOnc
Post-EBMT Highlights in Acute Myeloid Leukemia
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.